Riskpilot← Back to searchSign inGet full accessLIC SCADENTA AS
ASActiveOrg 956226635Hamangskogen 60, 1338 SandvikaWholesale of pharmaceutical and medical goods · NACE 4646Est. 199030 employees
Revenue 2024
NOK 171,9M
+16% vs 2023
EBITDA margin
10.0%
+24% vs 2023
Equity ratio
47.3%
Financial strength
Net profit 2024
NOK 42,6M
+305% vs 2023
| Revenue | NOK 171,9M | +16% |
| EBITDA | NOK 17,2M | +24% |
| Net profit | NOK 42,6M | +305% |
| Total assets | NOK 127,1M | +41% |
| Equity | NOK 60,2M | +0% |
| Employees | 30 | — |
Legal name
LIC SCADENTA AS
Org number
956226635
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. januar 1990
Share capital
—
Employees
30 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Address
Hamangskogen 60, 1338 Sandvika
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 157 724 | 159 174 | 153 496 | 148 459 | 171 874 |
| Staff expenses | −24 224 | −27 805 | −26 214 | −25 543 | −29 794 |
| EBITDA | 20 811 | 21 012 | 16 618 | 13 850 | 17 204 |
| Depreciation & amort. | −1 716 | −1 722 | −1 632 | −1 266 | −1 393 |
| EBIT | 19 094 | 19 290 | 14 985 | 12 584 | 15 811 |
| Net financials | 25 789 | 34 463 | 30 318 | 767 | 30 531 |
| Profit before tax | 44 883 | 53 752 | 45 303 | 13 351 | 46 342 |
| Tax | 4 246 | 4 254 | 3 293 | 2 841 | 3 776 |
| Net profit | 40 637 | 49 498 | 42 010 | 10 510 | 42 566 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 95 316 | 104 466 | 106 338 | 90 469 | 127 144 |
| Equity | 34 221 | 34 319 | 59 909 | 59 919 | 60 161 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 61 095 | 70 147 | 46 429 | 30 550 | 66 983 |
| Total debt | 61 095 | 70 147 | 46 429 | 30 550 | 66 983 |
EBITDA margin
10.0%
This company
15.8%
Market median
-37% vs market
20202024
Equity ratio
47.3%
This company
38.2%
Market median
+24% vs market
20202024
Return on equity
70.8%
This company
18.4%
Market median
+285% vs market
20202024
Net profit margin
24.8%
This company
8.1%
Market median
+206% vs market
20202024
Asset turnover
1.35×
This company
1.12×
Market median
+21% vs market
20202024
Debt / equity
1.11×
This company
0.62×
Market median
-79% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KF Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (1) | ||
AH Chief Executive Officer | Chief Executive Officer | 1993 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Former (1) | ||
| Board of Directors | 2020 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Dab Dental Ab | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
LIC SCADENTA AS 
OSLO DENTAL ASBoard members of LIC SCADENTA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kristian Funderud Melby | Chief Executive Officer | 0 companies |
| Arild Haugeland | Chief Executive Officer | 0 companies |
| Bjørn Myhre | Board of Directors | 0 companies |
| Frida Maria Agge | Board of Directors | 0 companies |
| Karl Jonas Redin | Chairman | 0 companies |